Literature DB >> 31501639

Flexibly Monitoring Group Sequential Survival Trials When Testing is Based Upon a Weighted Log-Rank Statistic.

Sean S Brummel1, Daniel L Gillen2.   

Abstract

We consider the repeated group sequential testing of a survival endpoint with a time-varying treatment effect using a weighted logrank statistic. The emphasis of this paper is on the monitoring of this statistic where information growth is non-linear. We propose using a constrained boundaries approach to maintain the planned operating characteristics of a group sequential design. A simulation study is presented to demonstrate the operating characteristics of the method together with a case study to illustrate the procedure. We show that when monitoring a weighted logrank statistic, the entry and survival distribution needs to be estimated at interim analyses.

Entities:  

Keywords:  62L05; 62L10; 62N03; Constrained boundaries; Group sequential; Information; Monitoring; Nonparametric; Nonproportional hazards; Survival; Weighted logrank

Year:  2014        PMID: 31501639      PMCID: PMC6732781          DOI: 10.1080/07474946.2014.856635

Source DB:  PubMed          Journal:  Seq Anal        ISSN: 0747-4946            Impact factor:   0.927


  7 in total

1.  Flexible implementations of group sequential stopping rules using constrained boundaries.

Authors:  Bart E Burington; Scott S Emerson
Journal:  Biometrics       Date:  2003-12       Impact factor: 2.571

2.  Frequentist evaluation of group sequential clinical trial designs.

Authors:  Scott S Emerson; John M Kittelson; Daniel L Gillen
Journal:  Stat Med       Date:  2007-12-10       Impact factor: 2.373

3.  Sequential monitoring of survival data with the Wilcoxon statistic.

Authors:  K K Lan; W F Rosenberger; J M Lachin
Journal:  Biometrics       Date:  1995-09       Impact factor: 2.571

4.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

5.  Implementation of group sequential logrank tests in a maximum duration trial.

Authors:  K K Lan; J M Lachin
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

6.  Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  T R Fleming; J D Neaton; A Goldman; D L DeMets; C Launer; J Korvick; D Abrams
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995

7.  A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  D I Abrams; A I Goldman; C Launer; J A Korvick; J D Neaton; L R Crane; M Grodesky; S Wakefield; K Muth; S Kornegay
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.